1.On the safety of oral cholerae vaccine produced at Company No1 of Vaccine and Biological Preparation
Journal of Practical Medicine 2003;445(3):44-45
During 2001-2002 period, 19 lots of oral cholera vaccines were prepared at the Company No1 of Vaccine and Biological Preparation. Weight gain tests were performed on white mice, each test used 20 mices for vaccine sample and 20 mices for control. According to WHO standards and Central National of Control for Biological Preparation standards, cholera vaccine does not cause death for mice, and mean weight of mouse after three days injection is at least equal to that of infection moment and the mean weight gain of the seventh day is higher or equal 60% of control. All 19 lots of vaccine had had high safety
Cholera Vaccines
;
Cholera
;
Biological Products
2.Chemical composition of oral cholera vaccine 2001-2002
Journal of Practical Medicine 2003;450(4):55-57
19 lots of oral vaccine producted in the years 2001-2002 at the Company No1 of Vaccines and Biological Preparations were studied. pH=6.9 in the lot 110102, the highest was 7.3 in the lots 050901, 060901 and 091201 (permissible pH=6.8-7.4); thimerosant content from 0.005 g% in the lot 020801 to 0.015 g% in the lots 110102, 120302 and 150502 (permissible content ≤ 0.02 g%); formaldehyde content from 0.005 g% in the lot 060901 to 0.017 g% in the lot 110102 (permissible content ≤ 0.02 g%); total protein content 0.77 g% in the lot 091201 and 1.63 g% in the lot 181002 (permissible content ≤ 2 g%)
Cholera Vaccines
;
chemistry
;
Biological Products
3.Chemical composition of oral cholera vaccine 2001-2002
Journal of Practical Medicine 2003;450(4):57-59
At Cho Ray Hospital – Ho Chi Minh city from Dec 2001 to Dec 2002, 228 heart failure cases (96 males, 130 females, aged 58.4317.45) were studied. Their associated conditions were: 14 with diabetes, 5 brain blood infactus, 5 hyperthyroidies, 19 kidney failures. Among 162 patients with electrolyte disorders, 25 were died, the rate of hyponatremia and hyperkalemia was significantly higher in fatal group than in survival group. Hyponatremia was fatal risk factor and it should pay great attention to treat this condition with hypertonic natrium solution
Cholera Vaccines
;
chemistry
;
Biological Products
4.The efficiency of oral cholera vaccine produced industrial scale
Journal of Practical Medicine 2003;450(4):59-60
Oral cholera vaccine efficiency was studied with the strains of V. cholerae 01, Cairo 50, V. cholerae 01.569B, V. cholerae 01 Phil 6973, El Tor, as antigene. According to the standards issued by the National Centre of Control of Medical Biopreparation, the samples of vaccine producted at industrial scale in the Company No1 of Vaccines and Biological Preparation belong the National Institute of Hygiene and Epidemiology was satisfied
Cholera Vaccines
;
chemistry
;
Biological Products
;
5.To purify Japanese encaphalitis virus for vaccine production at semiindustrial scale
Journal of Practical Medicine 2003;445(3):19-20
42 lots of Japaness encaphalitis virus were purified from viral infected rat brain mixture, for obtaining 28 lots of vaccine products. All lots of vaccine were met WHO standard through local and national laboratory qualification ultracentrifugal 126000 g within 5 hours demonstrated that saturated ammonium sulphate precipitated procedure had removed 26.4% to 32% of protein, then ultricentyrifugal sucrose had removed almost the rest. Protein contents in producted vaccine reached 6.53-61.3%
Encephalitis, Japanese
;
Encephalitis Virus, Japanese
;
Viruses
;
Vaccines
6.Respiratory virus laboratory pandemic planning and surveillance in central Viet Nam, 2008–2010
Tran Thomas ; Chien Bui Trong ; Papadakis Georgina ; Druce Julian ; Birch Chris ; Chibo Doris ; An Truong Phuoc ; Trang Le Thi Kim ; Trieu Nguyen Bao ; Thuy Doan Thi Thanh ; Catton Mike ; Mai Trinh Xuan
Western Pacific Surveillance and Response 2012;3(3):49-56
Introduction: Laboratory capacity is needed in central Viet Nam to provide early warning to public health authorities of respiratory outbreaks of importance to human health, for example the outbreak of influenza A(H1N1) pandemic in 2009. Polymerase chain reaction (PCR) procedures established as part of a capacity-building process were used to conduct prospective respiratory surveillance in a region where few previous studies have been undertaken. Methods: Between October 2008 and September 2010, nose and throat swabs from adults and children (approximately 20 per week) presenting with an acute respiratory illness to the Ninh Hoa General Hospital were collected. Same-day PCR testing and result reporting for 13 respiratory viruses were carried out by locally trained scientists. Results: Of 2144 surveillance samples tested, 1235 (57.6%) were positive for at least one virus. The most common were influenza A strains (17.9%), with pandemic influenza A(H1N1) 2009 and seasonal H3N2 strain accounting for 52% and 43% of these, respectively. Other virus detections included: rhinovirus (12.4%), enterovirus (8.9%), influenza B (8.3%), adenovirus (5.3%), parainfluenza (4.7%), respiratory syncytial virus (RSV) (3.9%), human coronavirus (3.0%) and human metapneumovirus (0.3%). The detection rate was greatest in the 0–5 year age group. Viral co-infections were identified in 148 (6.9%) cases. Discussion: The outbreak in 2009 of the influenza A(H1N1) pandemic strain provided a practical test of the laboratory’s pandemic plan. This study shows that the availability of appropriate equipment and molecular-based testing can contribute to important individual and public health outcomes in geographical locations susceptible to emerging infections.
7.Study on the proportion of patients with uncontrolled hypertension among outpatients and related factors at the Internal Medicine Clinic, Hue university of medicine and Pharmacy Hospital
Vu Thao Vy NGUYEN ; Thi Bich Thuy LE ; Pham Phuoc Long DOAN ; Thi Thanh Nhan TRAN ; Phuoc Thuoc DOAN
Hue Journal of Medicine and Pharmacy 2023;13(7):190-197
Background: Hypertension is one of the dangerous chronic diseases. In the treatment of hypertension, controlling blood pressure to achieve treatment target is paramount to prevent dangerous complications and death. The study was conducted to identify the percentage of hypertensive patients who do not achieve treatment target among outpatients at the internal medicine clinic, Hue University of Medicine and Pharmacy Hospital, and explore some related factors. Methods: A cross-sectional study was conducted among 403 hypertensive patients treated as outpatients at the internal medicine clinic. A multivariate logistic regression model was used to identify the related factors. Results: 46.4% of hypertensive patients did not reach the treatment target. Factors related to uncontrolled hypertension were male, non-religion, comorbidities, no reduction in salt intake, the use of coffee/tea, and non-compliance with medication (p < 0.05). Conclusions: The rate of patients with uncontrolled hypertension was still high. The health sector should consider establishing an outpatient management team; strengthening communication activities and advice on diet and drug use in parallel with medical examination and treatment.
8.Triterpenoids isolated from the aerial parts of Buxus latistyla Gagnep.
Quoc Hung VO ; Thuy Vi HUYNH ; Ngoc Minh Thao DOAN ; Thi Bich Nguyet HUYNH ; Thi Minh Hieu NGUYEN ; Thi Nhat Le DOAN
Hue Journal of Medicine and Pharmacy 2023;13(6):72-
Background: Buxus latistyla Gagnep. (Buxaceae) has been used as a remedy for treating malaria, haemoptysis, amoebic dysentery etc. However, its chemical constituents are still unknown. Thus, the aim of this study was to identify phytochemicals isolated from this plant. Materials and method: Aerial parts of B. latistyla were collected from Quang Tri province. Pure compounds were isolated using the combination of chromatographic methods. Structures of isolated compounds were identified by analyzing spectral data of nuclear magnetic resonance as well as by comparing with reported data. Results & Conclusion: Five triterpenes were isolated and identified including lupeol (1), lupenone (2), betulin (3), 20(29)-lupene-2α,3α-diol (4), 20(29)-lupene-2α,3α,28-triol (5). This is the first report about those phytochemicals of B. latistyla collected in Vietnam.
9.Microscopic characteristics, chemical compositions and bioactivities of Alpinia vietnamica
Dinh Quynh Phu NGUYEN ; Hoai Bao Chau NGUYEN ; Quoc Tuan DOAN ; Khanh Thuy Linh NGUYEN ; Van Nguyen TRAN ; Thi Khanh Linh LE
Hue Journal of Medicine and Pharmacy 2023;13(6):79-
Background: The genus Alpinia is one of the diverse genera in Thua Thien Hue province, in which many species have been used as medicine. But until now, studies on A. vietnamica have rarely been reported. Objectives: The present study was aimed at the determination of microscopic characteristics and chemical compositions as well as evaluating the antioxidant and acetylcholinesterase inhibitory activities of A. vietnamica. Materials and methods: A. vietnamica was collected in Phong Dien district, Thua Thien Hue province. Anatomic structures and powder properties were determined by the microscopic method. Phytochemical screening was conducted by specific chemical reactions. The Folin-Ciocalteau method and the aluminum chloride-flavonoid assay, respectively, were used to quantify the total polyphenol (TPC) and total flavonoid contents (TFC). Antioxidant activity was assessed using the DPPH assay, while acetylcholinesterase (AChE) inhibitory activity was evaluated using the Ellman method. Results: The microscopic characteristics of this species have been described. Phytochemical analysis results revealed the presence of flavonoids, coumarins, and tannins in A. vietnamica. The ethanol extract from the aerial part of A. vietnamica had higher polyphenol and flavonoid contents than the underground part extract. Moreover, this extract also displayed a stronger DPPH radical scavenging and exhibited AChE inhibitory activities. Conclusion: This is the first report on the microscopic characteristics, chemical compositions, and biological activities of A. vietnamica.
10.Study on the effective control of postpreal blood glucose of resistant starch cakes in patients with type 2 diabetes
Huu Dung TRAN ; Quang Hung LE ; Bao Dung VO ; Hoang Vu NGUYEN ; Thanh Bao Yen LUONG ; That Hy TON ; Phuoc Hieu DOAN ; Thi Bich Hien PHAM ; Huu Tien NGUYEN ; Hai Thuy NGUYEN
Hue Journal of Medicine and Pharmacy 2023;13(7):52-58
Background: This study was conducted on 93 volunteers with type 2 diabetes to investigate the ability of acetylated wheat starch cake containing 32.1% resistant starch to control postprandial blood glucose levels. Material and methods: The study was designed using a crossover, double-blind trial method. During each testing day, after a minimum of 12 hours of overnight fasting, each participant consumed two identical cakes containing either 80 g of acetylated wheat starch or 80 g natural wheat starch with 330ml of water within 15 minutes. Blood glucose levels were measured at baseline, 60 mins (G1), and 120 mins (G2) after ingestion. The predictive value of factors that contribute to the ability of resistant starch to control postprandial blood glucose was determined by the area under the receiver operating characteristic (ROC) curve based on the combined effect of the cake weight-to-BMI ratio (g/m²BMI) and HbA1c. Results: 60 mins and 120 mins postprandial capillary glucose levels after consuming acetylated wheat starch cake (10.4 ± 1.2 và 9.2 ± 1.2 mmol/L, respectively) were significantly lower compared with natural wheat starch cake (13.3 ± 1.8 và 11.2 ± 1.8 mmol/L, respectively) (p < 0.05). For good control of postprandial blood glucose levels, a maximum of 80 g of acetylated wheat starch can be used per serving for patients with type 2 diabetes with HbA1c ≤ 7.25 without blood glucose-lowering medication is required. Conclusion: acetylated wheat starch has better ontroled of postprandial blood glucose compared with natural wheat starch in patients with type 2 diabetes. This is very suitable in the processing of diets including resistant starch for patients with type 2 diabetes for the purpose of both supporting treatment and improving quality of life.